Acumen Pharmaceuticals (ABOS) Depreciation & Amortization (CF) (2021 - 2026)
Acumen Pharmaceuticals (ABOS) reported Depreciation & Amortization (CF) of $12000.0 for Q1 2026, down 20.0% on a YoY basis from $15000.0 in Q1 2025, and little changed sequentially from $12000.0 in Q4 2025.
Acumen Pharmaceuticals (ABOS) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $12000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 20.0% year-over-year to $12000.0; the trailing twelve-month figure through Mar 2026 stood at $55000.0 (down 11.29% YoY), and the FY2025 full-year result was $58000.0, down 7.94% from the prior year.
- Depreciation & Amortization (CF) was little changed at $12000.0 in Q1 2026, from $12000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $19000.0 in Q4 2023 to a low of $4000.0 in Q1 2022.
- A 5-year average of $13294.1 and a median of $14000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 300.0% in 2022 and decreased 26.32% in 2024, its largest moves.
- Tracing ABOS's Depreciation & Amortization (CF) over 5 years: stood at $12000.0 in 2022, then soared by 58.33% to $19000.0 in 2023, then decreased by 26.32% to $14000.0 in 2024, then declined by 14.29% to $12000.0 in 2025, then changed by 0.0% to $12000.0 in 2026.
- Business Quant data shows ABOS's Depreciation & Amortization (CF) at $12000.0 in Q1 2026, $12000.0 in Q4 2025, and $15000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | - |
| 10 | Acumen Pharmaceuticals | 140.98 Mn | 140.98 Mn | - | 12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |